ReviewJournal of Cancer2021
Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?
Review in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Primary Carcinomas of the Episiotomy Scar Site: A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Exploring the Utility of ALDH1 as a Marker for the Cancer Stem Cell Population in OCCC Cell Lines.Cells · 2026Article
- Enhancing the positive predictive value of early-stage ovarian cancer detection using a two-step machine learning framework.Journal of translational medicine · 2026Article
- Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort.JCO precision oncology · 2026Article
- Prognostic imaging features of ovarian clear cell carcinoma on multiparametric MRI.Abdominal radiology (New York) · 2026Article
- Analysis of prognostic factors in ovarian clear cell carcinoma: a retrospective cohort study.Translational cancer research · 2026Article
- Exosome-Enriched Hub Gene Networks Identify Diagnostic Biomarkers and Repurposable Therapeutic Targets in Endometriosis.International journal of molecular sciences · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies.Journal of translational medicine · 2026Article
- Diversity within ovarian cancer subtypes and their tumor microenvironment.Frontiers in oncology · 2026Review
- From Inflammation to Malignancy: The Link Between Endometriosis and Gynecological Cancers.International journal of molecular sciences · 2025Review
- Association between endometriosis and prognosis of ovarian clear cell carcinoma: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Endometriosis: An Immunologist's Perspective.International journal of molecular sciences · 2025Review
- Fatty Acid Metabolism Regulators Have Pivotal Roles in the Pathogenesis of Ovarian Carcinoma.International journal of molecular sciences · 2025Article
- Ovarian Cancer-Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors' Molecular Backgrounds.International journal of molecular sciences · 2025Review
- Long-Term Survival of Endometriosis-Related Ovarian Clear Cell Carcinoma with Endometriosis Surgical History.Journal of clinical medicine · 2025Article
- MZB1 regulates the immune microenvironment and inhibits ovarian cancer cell migration.Open medicine (Warsaw, Poland) · 2025Article
- Enhanced prognostic stratification in early-stage epithelial ovarian cancer: multi-histological analysis of neutrophil-to-lymphocyte ratio with particular emphasis on clear cell histology.American journal of cancer research · 2025Article
- Mesenchymal stromal cells as cancer promoters.Oncogene · 2024Review
- Case report: Malignant transformation of ovarian endometrioma during long term use of dienogest in a young lady.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is an estrogen-dependent disease, which serves as a precursor of ovarian cancer, especially clear cell carcinoma (OCCC) and endometrial carcinoma. Although micro-environmental factors such as oxidative stress, immune cell dysfunction, inflammation, steroid hormones, and stem cells required for malignant transformation have been found in endometriosis, the exact carcinogenic mechanism remains unclear. Recent research suggest that many putative driver genes and aberrant pathways including ARID1A mutations, PIK3CA mutations, MET activation, HNF-1β activation, and miRNAs dysfunction, play crucial roles in the malignant transformation of endometriosis to OCCC. The clinical features of OCCC are different from other histological types. Patients usually present with a large, unilateral pelvic mass, and occasionally have thromboembolic vascular complications. OCCC patients are easier to be resistant to chemotherapy, have a worse prognosis, and are usually difficult to treat. To improve the survival of OCCC patients, it is necessary to better understand its specific carcinogenic mechanism and explore new treatment strategy, including molecular target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.